| Ytd | 80.78% | |
| 1y | 142.51% |
| Open | 14.09 | Prev Close | 14.16 | Low | 13.71 | High | 14.16 | Mkt Cap | 1.17B |
| Vol | 226.34K | Avg Vol | 1.09M | EPS | -0.64 | P/E | N/A | Forward P/E | -13.26 |
| Beta | 0.87 | Short Ratio | 22.00 | Inst. Own | 86.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 14.25 | 200-d Avg | 13.65 | 1yr Est | 33.14 |
CRVS News
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PT
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference ca
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) were up 5.1% during mid-day
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announ
SOUTH SAN FRANCISCO, Calif. , June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:
Corvus Pharmaceuticals, Inc. remains a Sell as its valuation has run ahead of fundamentals following
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to inc
Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive dat
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soqu
Stocks traded higher with Dow Jones up by 1,000 points. Consumer discretionary shares rose while ene
The Dow Jones index rose 700 points, Autoliv Inc (NYSE: ALV) reported strong results causing a jump
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) have been given a consensus
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price fell 6.5% during trading
